טוען...
Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose‐limiting toxicity (DLT) and the recommended dose (RD) of sonidegib in Asian patients with advance...
שמור ב:
| הוצא לאור ב: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084670/ https://ncbi.nlm.nih.gov/pubmed/27467121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13022 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|